Pancreatic Cell News Volume 11.30 | Aug 11 2020

    By
    Justin.choi
    -
    0
    104







    2020-08-11 | PACN 11.30


    Pancreatic Cell News by STEMCELL Technologies
    Vol. 11.30 – 11 August, 2020
    TOP STORY

    Loss of HIF1A from Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis

    Scientists studied the roles of hypoxia inducible factor 1 alpha (HIF1A) in development of pancreatic tumors in mice. Cancer cells were cultured from pancreatic ductal adenocarcinomas from mice and analyzed in cell migration and invasion assays and by immunoblots, real-time PCR, and liquid chromatography–mass spectrometry.
    [Gastroenterology]

    Abstract

    Watch 'collaborating to accelerate COVID-19 research'
    PUBLICATIONSRanked by the impact factor of the journal

    Circulating Unmethylated CHTOP and INS DNA Fragments Provide Evidence of Possible Islet Cell Death in Youth with Obesity and Diabetes

    The authors identified the CHTOP gene as a candidate whose CpGs showed a greater frequency of unmethylation in human islets. A digital PCR strategy was used to determine the methylation pattern of CHTOP and INS CpG sites in primary human tissues.
    [Clinical Epigenetics]

    Full Article

    Regulated Expression and Function of the GABAB Receptor in Human Pancreatic Beta Cell Line and Islets

    Scientists generated a new stable human beta cell line from neonatal pancreas. This cell line, named ECN90, expressed both subunits (GABBR1 and GABBR2) of the metabotropic GABAB receptor compared to human islet.
    [Scientific Reports]

    Full Article

    Role of Sirtuin-1 (SIRT1) in Hypoxic Injury in Pancreatic β-Cells

    Hypoxic damage significantly increased the TNF-α, IL-6 and reactive oxygen species levels in INS-1 cells. However, the reduced cell viability and increased inflammatory cytokines from hypoxic damage were ameliorated by SIRT1 activation in INS-1 cells.
    [Journal of Drug Targeting]

    Full Article

    Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer

    Scientists showed that expression of the TPR-NTRK1 fusion kinase in immortalized mouse pancreatic ductal epithelial or mouse lung epithelial cells was sufficient to promote rapidly growing tumors in mice.
    [Cell Reports]

    Full ArticleGraphical Abstract

    miR-324-5p Contributes to Cell Proliferation and Apoptosis in Pancreatic Cancer by Targeting KLF3

    The authors report that miR-324-5p regulated the proliferation and apoptosis of pancreatic cancer cells through regulating the expression of KLF3.
    [Molecular Therapy-Oncolytics]

    AbstractGraphical Abstract

    Low Glucose Enhanced Metformin’s Inhibitory Effect on Pancreatic Cancer Cells by Suppressing Glycolysis and Inducing Energy Stress via Up-Regulation of miR-210-5p

    To explore mechanisms underlying the discrepancy in anti-tumor effects of metformin on pancreatic cancer cells under different glucose conditions, investigators cultured PANC-1 cells in 25 mM and 5 mM glucose media, then treated them with or without metformin.
    [Cell Cycle]

    Full Article

    Virtual Conference Exhibition: Pluripotent Stem Cells
    REVIEWS

    Aptamers: A Novel Targeted Theranostic Platform for Pancreatic Ductal Adenocarcinoma

    The authors summarize the generation process of aptamers and their application as biosensors, biomarker detection tools, targeted imaging tracers, and drug-delivery carriers. They discuss the current implementation aptamers in clinical trials, their limitations and possible future utilization, with a focus on pancreatic ductal adenocarcinoma.
    [Radiation Oncology]

    Full Article

    INDUSTRY AND POLICY NEWS

    AzurRx BioPharma Announces Positive Interim Data from First Patient Cohort in Phase II Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

    AzurRx BioPharma, Inc. announced positive results from the first five patients in its Phase II combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency in patients with cystic fibrosis.
    [AzurRx BioPharma]

    Press Release

    PharmaCyte Biotech Ready to Submit Investigational New Drug Application to FDA for Clinical Trial in Pancreatic Cancer

    PharmaCyte Biotech has submitted an Investigational New Drug Application to the US FDA. They request a planned Phase IIb clinical trial in locally advanced, inoperable pancreatic cancer, the third leading cause of cancer-related deaths in the US.
    [Pharmacyte Biotech (GlobeNewswire, Inc.)]

    Press Release

    FEATURED EVENT

    NCRI 2020: Virtual Showcase

    November 2 – November 3
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Researcher – Pancreatic Cancer Biology

    New York University School of Medicine – New York, New York, United States

    Postdoctoral Associate – Immunology and Cancer Biology

    University of Miami Health System – Miami, Florida, United States

    Assistant Director – Mass Spec Core Facility

    Cold Spring Harbor Laboratory – New York, New York, United States

    Postdoctoral Fellow – Pancreatic and Liver Malignancies

    Weill Cornell Medicine – New York, New York, United States

    Lab Manager – Pancreatic Ductal Adenocarcinoma

    Cold Spring Harbor Laboratory – Long Island, New York, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Pancreatic Cell News Twitter